Chronic heart rate reduction remodels ion channel transcripts in the mouse sinoatrial node but not in the ventricle

Physiological Genomics

Volumn 24, Issue 1, 2005, Pages 4-12

  Leoni, Anne Laure ^a   Marionneau, Céline ^a   Demolombe, Sophie ^a   Le Bouter, Sabrina ^a   Mangoni, Matteo E ^b   Escande, Denis ^a   Charpentier, Flavien ^a  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Electrocardiogram; Gene expression; Ivabradine

Indexed keywords

CATION CHANNEL; CONNEXIN 43; ION CHANNEL; IVABRADINE; POTASSIUM CHANNEL;

ALPHA CHAIN; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; CLUSTER ANALYSIS; CONTROLLED STUDY; ELECTROCARDIOGRAM; GENE; GENE EXPRESSION; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE; HEART VENTRICLE REMODELING; HYPERPOLARIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINUS NODE; TELEMETRY; UPREGULATION;

ANIMALIA;

EID: 33645754478     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00161.2005     Document Type: Article

References (48)

1. Allessie M, Ausma J, and Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54: 230-246, 2002.
2. Bois P, Bescond J, Renaudon B, and Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 118: 1051-1057, 1996.
3. Borer JS, Fox K, Jaillon P, and Lerebours G (for the Ivabradine Investigators Group). Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107: 817-823, 2003.
4. Bucchi A, Baruscotti M, and DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol 120: 1-13, 2002.
5. Cho HS, Takano M, and Noma A. The electrophysiological properties of spontaneously beating pacemaker cells isolated from mouse sinoatrial node. J Physiol 550: 169-180, 2003.
6. Demolombe S, Marionneau C, Le Bouter S, Charpentier F, and Escande D. Functional genomics of cardiac ion channel genes. Cardiovasc Res 67: 438-447, 2005.
7. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol 55: 455-472, 1993.
8. f channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities. Br J Pharmacol 142: 107-112, 2004.
9. Duff HJ, Offord J, West J, and Catterall WA. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle. Mol Pharmacol 42: 570-574, 1992.
10. Eisen MB, Spellman PT, Brown PO, and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 14: 863-868, 1998.
11. Gardiner SM, Kemp PA, March JE, and Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol 115: 579-586, 1995.
12. + channel Kv1.5. J Biol Chem 278: 47046-47052, 2003.
13. Hagiwara N, Irisawa H, and Kameyama M. Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol 395: 233-253, 1998.
14. 2+ release from sarcoplasmic reticulum in the regulation of sinoatrial node automaticity. Heart Vessels 11: 234-241, 1996.
15. 2+ channels. Neuron 31: 35-45, 2001.
16. Kodama I, Kamiya K, and Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 35: 13-29, 1997.
17. Lacroix D, Gluais P, Marquie C, D'Hoinne C, Adamantidis M, and Bastide M. Repolarization abnormalities and their arrhythmogenic consequences in porcine tachycardia-induced cardiomyopathy. Cardiovasc Res 54: 42-50, 2002.
18. Lande G, Demolombe S, Bammert A, Moorman A, Charpentier F, and Escande D. Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: Pharmacological profile. Cardiovasc Res 50: 328-334, 2001.
19. Le Bouter S, Demolombe S, Chambellan A, Bellocq C, Aimond F, Toumaniantz G, Lande G, Siavoshian S, Baró I, Pond AL, Nerbonne JM, Leger JJ, Escande D, and Charpentier F. Microarray analysis reveals complex remodeling of cardiac ion channel expression with altered thyroid status: relation to cellular and integrated electrophysiology. Circ Res 92: 234-242, 2003.
20. Le Bouter S, El Harchi A, Marionneau C, Bellocq C, Chambellan A, van Veen T, Boixel C, Gavillet B, Abriel H, Le Quang K, Chevalier JC, Lande G, Léger JJ, Charpentier F, Escande D, and Demolombe S. Long-term amiodarone administration remodels expression of ion channel transcripts in the mouse heart. Circulation 110: 3028-3035, 2004.
21. Leonoudakis D, Conti LR, Radeke CM, McGuire LM, and Vandenberg CA. A multiprotein trafficking complex composed of SAP97, CASK, Veli, and Mint1 is associated with inward rectifier Kir2 potassium channels. J Biol Chem 279: 19051-19063, 2004.
22. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, and Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109: 120-124, 2004.
23. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
24. f) in isolated mouse sino-atrial cells. Cardiovasc Res 52: 51-64, 2001.
25. Manz M, Reuter M, Lauck G, Omran H, and Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100: 149-155, 2003.
26. Marionneau C, Couette B, Liu J, Li H, Mangoni ME, Nargeot J, Lei M, Escande D, and Demolombe S. Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart. J Physiol 562: 223-234, 2005.
27. Mitchell GF, Jeron A, and Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol Heart Circ Physiol 274: H747-H751, 1998.
28. Monnet X, Ghaleh B, Colin P, de Curzon OP, Giudicelli JF, and Berdeaux A. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther 299: 1133-1139, 2001.
29. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109: 1674-1679, 2004.
30. Nagatsu M, Spinale FG, Koide M, Tagawa H, DeFreitas G, Cooper G 4th, and Carabello BA. Bradycardia and the role of β-blockade in the amelioration of left ventricular dysfunction. Circulation 101: 653-659, 2000.
31. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415: 219-226, 2002.
32. Nattel S, Khairy P, and Schram G. Arrhythmogenic ionic remodeling: adaptive responses with maladaptive consequences. Trends Cardiovasc Med 11: 295-301, 2001.
33. Nishikawa M, Mak JC, Shirasaki H, Harding SE, and Barnes PJ. Long-term exposure to norepinephrine results in down-regulation and reduced mRNA expression of pulmonary beta-adrenergic receptors in guinea pigs. Am J Respir Cell Mol Biol 10: 91-99, 1994.
34. Patberg KW and Rosen MR. Molecular determinants of cardiac memory and their regulation. J Mol Cell Cardiol 36: 195-204, 2004.
35. Pierce KL, Premont RT, and Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3: 639-350, 2002.
36. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, and Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 64: 192-203, 1998.
37. Remme WJ. Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. Cardiovasc Drugs Ther 17: 349-360, 2003.
38. Rosati B and McKinnon D. Regulation of ion channel expression. Circ Res 94: 874-883, 2004.
39. Schoenmakers M, Ramakers C, van Opstal JM, Leunissen JD, Londono C, and Vos MA. Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. Cardiovasc Res 59: 351-359, 2003.
40. Shinagawa K, Derakhchan K, and Nattel S. Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy. Pacing Clin Electrophysiol 26: 752-764, 2003.
41. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, and Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 275: 659-666, 1995.
42. Swynghedauw B. Myocardial remodelling: pharmacological targets. Expert Opin Investig Drugs 11: 661-674, 2002.
43. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, and Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 112: 37-42, 1994.
44. 2+ releases during diastolic depolarization of sinoatrial pacemaker cells do not require membrane depolarization. Circ Res 94: 802-809, 2004.
45. Vos MA, de Groot SH, Verduyn SC, van der Zande J, Leunissen HD, Cleutjens JP, van Bilsen M, Daemen MJ, Schreuder JJ, Allessie MA, and Wellens HJ. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 98: 1125-1135, 1998.
46. Witte K, Schnecko A, Hauth D, Wirzius S, and Lemmer B. Effects of chronic application of propranolol on beta-adrenergic signal transduction in heart ventricles from myopathic BIO TO2 and control hamsters. Br J Pharmacol 125: 1033-1041, 1998.
47. Workman AJ, Kane KA, Russell JA, Norrie J, and Rankin AC. Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. Cardiovasc Res 58: 518-525, 2003.
48. Zicha S, Xiao L, Stafford S, Cha TJ, Han W, Varró A, and Nattel S. Transmural expression of transient outward potassium current subunits in normal and failing canine and human hearts. J Physiol 561: 735-748, 2004.